Quick answer
There's no single “recovery peptide.” Recovery research is a category, not a compound, and it splits into two mechanism tiers operating at different scales: local tissue-repair signaling (BPC-157 and TB-500, both converging on cell migration through separate pathways) and the systemic growth-hormone axis (CJC-1295 no-DAC + Ipamorelin, which acts on GH/IGF-1 signaling relevant to repair models rather than at a wound site). Researchers study these together not because they're redundant, but because they aren't: a local-repair signal and a systemic hormonal variable speak to different parts of the same recovery question. This page maps the category. It isn't a dosing protocol, and it doesn't tell you how to combine anything.
The recovery-relevant compounds, mapped
Three compounds (four counting the two GH-axis halves separately) cover recovery-research from two different mechanism tiers. Each links to its own live page for the full mechanism, pharmacokinetics, and sourcing detail.
| Compound | Mechanism family | Scale | What it's studied for |
|---|---|---|---|
| BPC-157 | VEGF-driven angiogenesis, FAK-paxillin cell migration, nitric oxide modulation, cytoprotection | Local, tissue-level | Tendon/ligament, muscle, GI, bone, and vascular repair models |
| TB-500 | G-actin binding and cytoskeletal remodeling | Local, tissue-level | Cardiovascular repair, dermal and corneal wound healing, muscle repair |
| CJC-1295 no-DAC (Mod GRF 1-29) | GHRH-receptor agonism → cAMP/PKA cascade | Systemic, pituitary-level | Pulsatile GH release; systemic GH/IGF-1 signaling relevant to repair models |
| Ipamorelin | Selective GHS-R1a (ghrelin-receptor) agonism → calcium/IP3 cascade | Systemic, pituitary-level | Amplifies GH release without the cortisol/prolactin confound of older GH secretagogues |
Reading the table by scale is the useful lens. BPC-157 and TB-500 act on local tissue-level variables at the injury site. CJC-1295 and Ipamorelin act at the pituitary, raising the systemic GH signal that research models tie to repair capacity more broadly. That's the mechanistic reason the category maps to two tiers instead of one list of interchangeable options.
See BPC-157, TB-500, and CJC-1295 no-DAC (Mod GRF 1-29) and Ipamorelin for the full single-compound and stack detail.
Local tissue-repair: BPC-157 and TB-500
BPC-157 and TB-500 are the two compounds most associated with local, wound-site recovery research, and they get compared constantly for a reason: both converge on cell migration as a downstream outcome, but they get there through different machinery.
BPC-157 is multi-pathway. It upregulates VEGF (driving new blood-vessel formation into the repair site), activates FAK-paxillin signaling (the mechanistic step that lets cells migrate into damaged tissue), modulates nitric oxide, and shows cytoprotective effects against toxin exposure — strongest in gastrointestinal tissue, tracking with its gastric-juice origin. TB-500 is comparatively single-pathway: it binds G-actin and regulates the cytoskeletal remodeling that governs how quickly a cell can reorganize and move into a damaged area.
The complementary framing researchers use is that BPC-157 builds the vasculature and triggers the migration signal, while TB-500 upgrades the cytoskeletal machinery that carries the migration out. They're not two versions of the same tool — one is closer to the “build and signal” side of repair, the other to the “execute the movement” side. That's a mechanistic distinction, not a superiority claim; which one is relevant depends entirely on the tissue and research question. The BPC-157 vs TB-500 comparison covers the full side-by-side — mechanism, pharmacokinetics, tissue-focus differences, and an honest read on what the combination literature does and doesn't support — and the BPC-157 explainer goes deeper on BPC-157's four-pathway mechanism and the tissue types it's been studied in.
Systemic axis: the GH-secretagogue stack
The second tier operates at a completely different scale. CJC-1295 no-DAC (also called Mod GRF 1-29) and Ipamorelin don't act at a wound site. They act at the pituitary, and any repair-relevant effect is a downstream consequence of that.
Mod GRF 1-29 activates the GHRH receptor on pituitary somatotrophs, raising intracellular cAMP and triggering GH release. Ipamorelin activates a separate receptor — GHS-R1a, the ghrelin receptor — through a calcium/IP3 cascade. The two intracellular cascades converge on the same somatotroph and produce GH release that's greater than either compound alone, which is the receptor biology behind why the pair is researched together rather than singly. Growth hormone is a systemic signal, and the GH-axis literature studies it in relation to body composition, tissue-level repair variables, and the age-related decline in pulsatile GH release.
That's the category-level distinction from BPC-157 and TB-500: this stack doesn't target a tissue, it targets the hormonal axis that research models tie to tissue repair more broadly. The CJC-1295 + Ipamorelin explainer covers the full receptor mechanism, the no-DAC vs with-DAC naming distinction (they are pharmacologically different compounds), and why Ipamorelin's receptor selectivity is preferred over older GH secretagogues like GHRP-6.
Why researchers study these together — and what not to over-optimize
Local tissue-repair compounds and the GH axis show up in the same research conversation because they aren't redundant with each other. A local signal and a systemic driver aren't competing to do the same job, so studying them side by side lets a researcher isolate a tissue-level variable from a hormonal-axis variable instead of confounding the two. That's a rationale about mechanism, not a recommendation to combine specific compounds or a claim about what combining them produces. This page doesn't describe how to run a stack, at what doses, or on what schedule. That belongs to a study design, not a category map, and nothing here should be read as one.
The thing worth resisting is treating “recovery stack” as a checklist to fill out. More compounds is not automatically a more rigorous study — every additional compound in a protocol is another variable that has to be isolated to attribute an effect to the right mechanism. A research question about local wound healing doesn't need the GH axis in scope by default, and a question about systemic GH decline doesn't need BPC-157 or TB-500 in scope by default. The category map exists so a researcher can pick the tier that matches the actual research question, not so every recovery study defaults to running all of it.
Quality signals across the category
Mechanism differs across these compounds; the sourcing bar doesn't. For any compound in this category, the same three things determine whether a supply is fit for research use: HPLC purity above 98%, a batch-specific Certificate of Analysis tying identity and purity to the actual lot in hand (not a product-line certificate covering unrelated batches), and cold-chain discipline in transit given that all of these ship lyophilized and degrade with thermal exposure and freeze-thaw cycling.
Sourcing posture
The Peptide Lab runs in-house HPLC purity and identity testing on every batch before it's listed, with documentation tied to the specific lot — that's the standard, not an add-on. For researchers who want an added layer of confirmation on a given shipment, independent third-party US-lab certification is available at checkout as a flat $100-per-order option. The quality process page walks through that testing pipeline end to end, and the certificates page hosts the actual batch documentation rather than asking you to take a purity claim on faith. For the field-general version of how to read a COA once you have one — what each line item means and the red flags that signal repackaged material — see the peptide COA guide.
